

Information Regarding Clinical Trial

Title	“A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Ascending Doses of AZD4635 Both as Monotherapy and in Combination with Durvalumab in Patients with Advanced Solid Malignancies”
Protocol Number	D8730C00001 (REFMAL 435)
Sponsor	AstraZeneca
Investigator	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
Study Related Phone Numbers	479-587-1700 (24 hours)
Key Points for Study	Cohort K, K/D-randomly assigned to either mono or combo therapy Immune checkpoint naïve Progressed on at least 1 prior chemo Mandatory screening and on study Bx Must request slot